Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
Authors
Keywords
Cancer stem cells, Gene expression, Cancer treatment, Glioblastoma multiforme, Prostate cancer, Biomarkers, Colorectal cancer, Transcription factors
Journal
PLoS One
Volume 12, Issue 8, Pages e0180541
Publisher
Public Library of Science (PLoS)
Online
2017-08-03
DOI
10.1371/journal.pone.0180541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
- (2016) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
- (2015) V. V. Prabhu et al. CANCER RESEARCH
- Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2015) Jinhuang Chen et al. PLoS One
- A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis
- (2014) Taranjit S. Gujral et al. CELL
- A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
- (2014) D. C. Smith et al. CLINICAL CANCER RESEARCH
- Kruppel-like Factor-9 (KLF9) Inhibits Glioblastoma Stemness through Global Transcription Repression and Integrin α6 Inhibition
- (2014) Mingyao Ying et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- ID1 and ID3 Regulate the Self-Renewal Capacity of Human Colon Cancer-Initiating Cells through p21
- (2012) Catherine A. O'Brien et al. CANCER CELL
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Frizzled 4 Regulates Stemness and Invasiveness of Migrating Glioma Cells Established by Serial Intracranial Transplantation
- (2011) X. Jin et al. CANCER RESEARCH
- A somitic Wnt16/Notch pathway specifies haematopoietic stem cells
- (2011) Wilson K. Clements et al. NATURE
- High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer
- (2010) Christel van den Hoogen et al. CANCER RESEARCH
- Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
- (2008) F. Zeppernick et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started